New report provides to rising proof of iNKT cell remedy’s potential in strong tumors
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical firm pioneering allogeneic, off-the-shelf invariant pure killer T (iNKT) cell therapies, at this time introduced the publication of one other landmark case in Nature’s Oncogene describing a whole and sturdy remission in a affected person with metastatic, treatment-refractory testicular most cancers, following remedy with agenT-797, MiNK’s allogeneic iNKT cell remedy.
Full remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and a number of ICIs (anti–PD-1, anti–CTLA-4, and anti–TIGIT)
The publication, titled “Salvage remedy with allogeneic invariant pure killer T cells in a closely pre-treated germ cell tumor,” presents a affected person case from MiNK’s medical trial (NCT05108623). The affected person had progressed after a number of strains of remedy—together with platinum-based chemotherapy, autologous stem cell transplant, and a number of immune checkpoint inhibitors (anti–PD-1, anti–CTLA-4, and anti–TIGIT)—and acquired a single infusion of agenT-797 alongside nivolumab. The affected person achieved a whole medical, radiologic, and biochemical remission, with no proof of illness over two years later. Donor iNKT cells had been detectable as much as six months post-infusion, and remedy was well-tolerated with no cytokine launch syndrome (CRS) or graft-versus-host illness (GVHD).
“This case exemplifies the highly effective potential of iNKT cells in treating even essentially the most difficult cancers,” stated Dr. Benjamin Garmezy, Assistant Director of Genitourinary Analysis for Sarah Cannon Analysis Institute at SCRI Oncology Companions. “We noticed a exceptional response in a affected person who had exhausted customary and experimental remedies, providing compelling proof to additional pursue medical research of iNKT cell therapies in strong tumors.”
Sturdy Responses & Immune Activation in Stable Tumors with Allo-iNKT Remedy
These findings are a part of a rising physique of medical proof supporting the potential of agenT-797 in strong tumors. On the 2025 inaugural AACR Immuno-Oncology assembly, MiNK introduced information from its Part 2 trial in 2L gastric most cancers, demonstrating immune activation, elevated tumor infiltration, and early alerts of tumor management in sufferers beforehand refractory to checkpoint inhibitors. Notably, prolonged survival past 12 months was noticed in a number of sufferers—an final result not often seen on this setting. These medical observations had been additional bolstered in a separate peer-reviewed case report revealed in Oncogene, which described a affected person with metastatic gastric most cancers who achieved a 42% tumor discount and greater than 9 months of progression-free survival following a single infusion of agenT-797 together with nivolumab.
Collectively, these information spotlight the potential of agenT-797 to reshape the tumor microenvironment and ship sturdy medical exercise, even in closely pretreated, immunotherapy-resistant cancers. The continuing Part 2 trial in gastric most cancers (NCT06251973) is actively enrolling, with further readouts anticipated in upcoming months. You may entry the total publication right here.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical firm advancing a brand new class of allogeneic invariant pure killer T (iNKT) cell therapies and precision-targeted immune applied sciences. MiNK’s proprietary platform is designed to revive immune steadiness and drive cytotoxic responses throughout most cancers, immune-mediated illnesses, and pulmonary immune failure. The corporate’s lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell remedy at the moment in medical improvement for graft-versus-host illness (GvHD), strong tumors, and extreme pulmonary irritation. MiNK can also be advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery instruments that allow extremely particular immune focusing on throughout tumor and tissue varieties. With a scalable manufacturing course of and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is dedicated to delivering accessible, sturdy, and broadly relevant immune reconstitution therapies. For extra data, go to www.minktherapeutics.com or comply with us on X @MiNK_iNKT. Data necessary to buyers is routinely posted to our web site and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant pure killer T (iNKT) cell remedy that harnesses the twin energy of innate and adaptive immunity. iNKTs operate as “grasp regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and reminiscence. This distinctive biology permits a strong, pathogen-agnostic immune response that may be directed towards hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to supply accessible, transformative remedy choices. In medical trials, agenT-797 can bolster peripheral reminiscence T-cell activation, improve tumor infiltration, and doubtlessly enhance outcomes for sufferers with strong cancers (Cytryn et al., AACR IO 2024;Oncogene, 2024), in addition to cut back irritation in critically in poor health sufferers with extreme respiratory pathology (Nature Communications, 2024).
Ahead Trying Statements
This press launch accommodates forward-looking statements which might be made pursuant to the secure harbor provisions of the federal securities legal guidelines, together with statements concerning the therapeutic potential, anticipated profit, plans and timelines of iNKT cells. These forward-looking statements are topic to dangers and uncertainties that would trigger precise outcomes to vary materially. These forward-looking statements are topic to dangers and uncertainties, together with the components described underneath the Threat Elements part of the latest Kind 10-Okay, Kind 10-Q and the S-1 Registration Assertion filed with the SEC. MiNK cautions buyers to not place appreciable reliance on the forward-looking statements contained on this launch. These statements communicate solely as of the date of this press launch, and MiNK and Agenus with no obligation to replace or revise the statements, apart from to the extent required by regulation. All forward-looking statements are expressly certified of their entirety by this cautionary assertion.
CONTACT: Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com
